Tuberculosis (TB) currently stands as the ninth leading cause of death from a single infectious agent worldwide. In 2016, 1.3 million deaths were attributed to this disease and 6.3 million new cases of TB were reported by WHO (World Health Organization) (WHO, 2017). In Egypt, TB is established as a significant public health problem, after Hepatitis C Virus and schistosomiasis (WHO, 2010). The main challenges that hinder the accomplishment of current TB control programs are multidrug-resistant tuberculosis (MDR-TB), and extensively drugresistant tuberculosis (XDR-TB). MDR-TB is defined as resistance to the two most active anti-TB drugs; rifampicin (RIF) and isoniazid (INH). XDR-TB includes resistance to the afore mentioned plus resistance to any fluoroquinoloneF (FQ) and at least one of the second line injectable drugs (amikacin, kanamycin (KAN) or capreomycin) (Gandhi et al., 2010). According to the WHO, in 2016 there were 240,000 deaths attributed to MDR and RIF-resistant TB and 490,000 new MDR-TB cases, worldwide (WHO, 2017). In Egypt, it is reported that, in 2011, about 14 % of newly diagnosed patients had MDR and RIF-resistant TB subsequently, in 2016; about 20% of previously treated patients were found with the same strains (WHO, 2017). Currently, the diagnosis of MDR-TB and XDR-TB using phenotypic drugsusceptibility testing is time-consuming. Consequently, rapid diagnostic tools are essential for controlling MDR-TB and XDR-TB cases. For reasons that it is economical, prompt, dependable and an easily performed method, Resazurin microtiter assay (REMA) has gained interest in the determination of MDR-TB. The WHO also recommends it as one of the non-commercial diagnostic sensitivity test methods (WHO, 2011). The main cause for tuberculosis resistance is the mutation of genes encoding drug activating enzymes or drug targets (Ramasawamy and Musser, 1998). Several genes are identified to be concomitant to resistance to anti-TB drugs including rpsL and rrs for streptomycin resistance, rpoB for RIF resistance, katG, inhA, aphC, and kasA for INH resistance, pncA for pyrazinamide resistance, embB for ethambutol resistance, gyrA and gyrB to FQ resistance, tlyA for capreomycin resistance and eis for KAN resistance. In addition, the rrs A1401G mutation is associated with cross-resistance to KAN, amikacin and capreomycin (Ando et al.